Carotid body tumor other imaging findings: Difference between revisions
No edit summary |
m Bot: Removing from Primary care |
||
| Line 20: | Line 20: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Radiology]] | [[Category:Radiology]] | ||
Latest revision as of 20:49, 29 July 2020
|
Carotid body tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carotid body tumor other imaging findings On the Web |
|
American Roentgen Ray Society Images of Carotid body tumor other imaging findings |
|
Risk calculators and risk factors for Carotid body tumor other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Maria Fernanda Villarreal, M.D. [3]
Overview
Since paragangliomas including carotid body tumor are of neuroendocrine origin, they may have somatostatin surface receptor which can be detected as an area of intense radio-tracer uptake by the Indium-111 octreotide scan. This modality may be helpful in the diagnosis of multicentric or metastatic disease. It also may be used after the surgery to look for a residual tumor.
Other Imaging Findings
Since paragangliomas including carotid body tumor are of neuroendocrine origin, they may have somatostatin surface receptor which can be detected as an area of intense radio-tracer uptake by the Indium-111 octreotide scan. This scan may be helpful in the diagnosis of:[1]
- Multicentric tumor
- Metastatic disease
- Residual tumor after the surgery
The scan is sensitive for tumors greater than 1.5 cm.
References
- ↑ Wieneke, Jacqueline A.; Smith, Alice (2009). "Paraganglioma: Carotid Body Tumor". Head and Neck Pathology. 3 (4): 303–306. doi:10.1007/s12105-009-0130-5. ISSN 1936-055X.